BridgeBio Pharma, Inc.
For the period ended Jun 30, 2026. Filed Aug 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 10, 2026
BBIO$78.67+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Six Months Ended June 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Operating activities: | ||
| Net loss | $(322,446) | $(353,366) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 77,314 | 63,123 |
| Net loss from equity method investments | 24,718 | 35,745 |
| Noncash interest expense on deferred royalty obligations (1) | 81,218 | 50,050 |
| Change in fair value of the embedded derivative associated with the deferred royalty obligation | (5,730) | (5,499) |
| Amortization of debt discount and issuance costs | 3,745 | 3,056 |
| Depreciation and amortization | 2,239 | 2,601 |
| Noncash lease expense | 3,094 | 2,230 |
| Loss on extinguishment of debt | — | 21,155 |
| Dividend from investment in equity securities | — | (2,302) |
| Other noncash adjustments, net | 1,502 | 35 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable, net | (115,040) | (72,146) |
| Inventories | (28,166) | (16,582) |
| Prepaid expenses and other current assets | (20,227) | (22,745) |
| Other assets | (3,283) | (174) |
| Accounts payable | (9,026) | 16,516 |
| Accrued compensation and benefits | (25,755) | (15,637) |
| Accrued research and development liabilities | 23,032 | (2,977) |
| Operating lease liabilities | (3,674) | (3,117) |
| Deferred revenue | (4,300) | (6,491) |
| Other liabilities (2) | 52,405 | 26,609 |
| Net cash used in operating activities | (268,380) | (279,916) |
| Investing activities: | ||
| Purchases of marketable securities | (63,937) | (7,908) |
| Maturities of marketable securities | 39,600 | — |
| Payment for intangible assets | — | (6,095) |
| Purchases of property and equipment | (512) | (594) |
| Net cash used in investing activities | (24,849) | (14,597) |
| Financing activities: | ||
| Proceeds from issuance of 2033 Notes | 632,500 | — |
| Issuance costs and discounts associated with 2033 Notes | (13,227) | — |
| Proceeds from issuance of 2031 Notes | — | 575,000 |
| Issuance costs and discounts associated with 2031 Notes | — | (12,034) |
| Proceeds from royalty obligation under Royalty Purchase Agreement (as described in Note 9) | — | 300,000 |
| Issuance costs associated with royalty obligation under Royalty Purchase Agreement | — | (2,012) |
| Repayment of term loans | — | (459,000) |
| Repayments of deferred royalty obligations (3) | (33,082) | (2,005) |
| Repurchase of common stock | (210,003) | (48,276) |
| Repurchase of RSU shares to satisfy tax withholding | (8,341) | (3,771) |
| Proceeds from stock option exercises, net of repurchases | 27,812 | 9,680 |
| Proceeds from common stock issuances under ESPP | 5,466 | 3,237 |
| Transactions with noncontrolling interests | — | 1,550 |
| Net cash provided by financing activities | 401,125 | 362,369 |
| Net increase in cash, cash equivalents, and restricted cash | 107,896 | 67,856 |
| Cash, cash equivalents, and restricted cash at beginning of period | 572,140 | 683,244 |
| Cash, cash equivalents, and restricted cash at end of period | $680,036 | $751,100 |
(1)Including a related party amount of $10,936 for the six months ended June 30, 2026 (as described in Note 9).
(2)Including a related party amount of $5,626 for the six months ended June 30, 2026 (as described in Note 9).
(3)Including a related party amount of $(5,784) for the six months ended June 30, 2026 (as described in Note 9).
\
Condensed Consolidated Statements of Cash Flows
(Continued)
| Six Months Ended June 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Supplemental Disclosure of Cash Flow Information: | ||
| Cash paid for interest | $20,316 | $23,271 |
| Supplemental Disclosures of Noncash Investing and Financing Information: | ||
| Transfers to noncontrolling interests | $(5,464) | $(1,640) |
| Recognized intangible asset recorded to “Other current liabilities” | $— | $2,400 |
| Deferred and unpaid issuance costs recorded to “Other current liabilities” | $1,355 | $998 |
| Reconciliation of Cash, Cash Equivalents and Restricted Cash: | ||
| Cash and cash equivalents | $677,911 | $748,953 |
| Restricted cash — Included in “Prepaid expenses and other current assets” | 549 | 449 |
| Restricted cash — Included in “Other assets” | 1,576 | 1,698 |
| Total cash, cash equivalents and restricted cash at end of periods shown on the condensed consolidated statements of cash flows | $680,036 | $751,100 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.